politics

CVS to Reinstate Zepbound Coverage and Introduce Eli Lilly's Foundayo Pill

28 Mayıs 2026CNBC

CVS Health has announced that it will restore coverage for the weight-loss drug Zepbound starting October 1. Additionally, the company will include Eli Lilly's recently approved obesity medication, Foundayo, in its drug plans beginning June 1.
This move reflects CVS's commitment to providing access to essential medications for weight management.
The inclusion of Zepbound and Foundayo in CVS's drug plans comes at a time when obesity is being recognized as a critical public health issue. The pharmaceutical industry is responding with innovative solutions, and pharmacy benefit managers like CVS are adapting their offerings to meet the changing needs of patient…
The decision by CVS to reinstate coverage for Zepbound and add Foundayo to its drug plans signals a growing recognition of the importance of obesity treatment options in the healthcare landscape. As obesity rates continue to rise, the inclusion of these medications could significantly impact patient outcomes and hea…

NewsAI özeti

This article is for informational purposes only and does not constitute medical advice.

Tam teknik rapor ve canlı veriler için yayıncının web sitesini ziyaret edin.

Her yerde okuyun. iOS ve Android için ödüllü uygulamalarımızı indirin.